CMS will reimburse providers $502 per test. The payment decision follows a joint FDA and CMS review pilot program. Cologuard became the first technology to gain approval through this process.
“CMS’ final payment decision represents a major milestone by providing 50 million Medicare patients access to this noninvasive colorectal cancer screening option,” said Kevin Conroy, president, CEO and chairman of Exact Sciences.
More articles on gastroenterology:
What can GI physicians do to boost GERD awareness?
Financial leadership playbook: The essential skills for a CFO in gastroenterology
Higher Medicaid reimbursement associated with higher cancer screening rates
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
